Ambio Announces US FDA Approval of a Generic Version of Forteo® (Teriparatide Injection) for Its Partner Apotex

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

Managed Care

General Health

Health

FDA

Apotex

More Like This

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function

Business Wire associated0

Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

GlobeNewswire associated0

Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen

Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®

Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.

PR Newswire associated0

Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval

Fortrea Increases Patient Access Capabilities and Cold Chain Expertise with FortreaRx™ Expansion